Drug discovery is a complex and time-consuming process that involves the identification of new drug candidates and the optimization of their properties. One of the key steps in this process is high-throughput screening, which allows researchers to test large numbers of compounds quickly and efficiently. However, the data generated by high-throughput screening can be overwhelming, making it difficult to identify promising drug candidates. This is where Visikol comes in.
Visikol is a contract research services company that specializes in advanced tissue imaging and advanced cell culture services to accelerate the drug discovery and development process. The company provides end-to-end services that include 3D tissue imaging, multiplex tissue imaging, digital pathology, high content imaging, 2D cell culture assays, 3D cell culture assays, and ex vivo tissue slice assays. Visikol’s expertise lies in transforming tissues into actionable insights and bridging the gap between in vitro assays and in vivo results through the use of best-in-class cell culture models.
AI and Machine Learning
One of the ways that Visikol is improving high-throughput screening is by incorporating AI and machine learning into its imaging and computational image processing pipeline. By integrating data generated with AI and machine learning tools, Visikol is able to analyze large amounts of data quickly and efficiently, identifying promising drug candidates more quickly than traditional methods.
Visikol is also using robotics and automation to seed cells and deliver compounds to microplates, further improving the efficiency of high-throughput screening. This approach aids pharmaceutical research in solving drug discovery problems with high specificity and sensitivity with high temporal and spatial resolutions. The idea at Visikol is to help the drug discovery process to “fail faster” by being able to visualize tangible changes at the cellular level.
AI and Drug Discovery
The use of AI and machine learning in drug discovery has the potential to revolutionize the field. By analyzing large amounts of data quickly and efficiently, researchers can identify promising drug candidates more quickly than traditional methods. By incorporating these tools into its imaging and computational image processing pipeline, Visikol is helping to accelerate the drug discovery and development process.
Visikol’s contract research services can help pharmaceutical companies, pharmaceutical scientists, biochemists, medicinal chemists, pharmacologists, and toxicologists in drug discovery and development. By using advanced imaging and image analysis, 3D cell culture models, and AI-enhanced digital pathology, Visikol is able to provide end-to-end services that accelerate the drug discovery and development process. If you’re interested in learning more about Visikol’s services, reach out to a member of our team!